Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

DNA methylation in primary myelofibrosis is partly associated with driver mutations and distinct from other myeloid malignancies II

ABSTRACT: DNA methylation in primary myelofibrosis is partly associated with driver mutations and distinct from other myeloid malignancies II

PROVIDER: PRJNA1164678 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

DNA methylation in primary myelofibrosis is partly associated with driver mutations and distinct from other myeloid malignancies

Project description:DNA methylation in primary myelofibrosis is partly associated with driver mutations and distinct from other myeloid malignancies

| PRJNA1164705 | ENA

DNA methylation in primary myelofibrosis is partly associated with driver mutations and distinct from other myeloid malignancies I

Project description:DNA methylation in primary myelofibrosis is partly associated with driver mutations and distinct from other myeloid malignancies I

| PRJNA1164666 | ENA

DNA methylation in primary myelofibrosis is partly associated with driver mutations and distinct from other myeloid malignancies I

Project description:Primary myelofibrosis (PMF) is a clonal blood disorder linked to mutually exclusive mutations in JAK2, CALR, or MPL genes. To understand the epigenetic effects of these mutations, we analyzed DNA methylation (DNAm) profiles of PMF patients. Notably, no differences were found between JAK2 and CALR mutated cases, whereas MPL mutations showed distinct DNAm patterns. Further investigation in induced pluripotent stem cell (iPSC) models with JAK2 mutations revealed only a moderate link to PMF-related epigenetic changes, suggesting these alterations are not directly caused by the mutations. Additionally, PMF-associated epigenetic changes showed minimal correlation with allele burden and were largely evoked by changes in the cellular composition. When comparing PMF DNAm profiles with those from other myeloid malignancies, such as acute myeloid leukemia, juvenile myelomonocytic leukemia, and myelodysplastic syndrome, many overlapping changes were found, making it difficult to distinguish PMF based on individual CpGs. However, a PMF score created by combining five CpGs successfully differentiated PMF from other diseases in training and validation datasets. These findings demonstrate that PMF driver mutations do not directly evoke epigenetic changes. While PMF shares epigenetic changes with other myeloid malignancies, epigenetic signatures can effectively differentiate PMF from related diseases.

2025-05-07 | GSE277841 | GEO

DNA methylation in primary myelofibrosis is partly associated with driver mutations and distinct from other myeloid malignancies II

2025-05-07 | GSE277866 | GEO

DNA methylation in primary myelofibrosis is partly associated with driver mutations and distinct from other myeloid malignancies.

Project description: Not available

| S-EPMC12048995 | biostudies-literature

DNA methylation in primary myelofibrosis is partly associated with driver mutations and distinct from other myeloid malignancies

Project description:This SuperSeries is composed of the SubSeries listed below.

2025-05-07 | GSE277889 | GEO

Clinical drug response and proteotype profiling elucidates targetable vulnerabilities of myelofibrosis

Project description:Myelofibrosis (MF) is a hematopoietic stem cell disorder belonging to the myeloproliferative neoplasms. MF patients frequently carry driver mutations in JAK2 and Calreticulin (CALR) and have limited therapeutic options. Here, we integrate ex vivo drug response and proteotype analyses across MF patient cohorts to discover targetable vulnerabilities and associated therapeutic strategies. Drug sensitivities of mutated and progenitor cells were measured in patient blood using high-content imaging and single-cell deep learning-based analyses. Integration with matched molecular profiling revealed three therapeutic vulnerabilities. First, CALR mutations drive BET and HDAC inhibitor sensitivity, particularly in the absence of high MAPK-Ras pathway protein levels. Second, an MCM complex-high proliferative signature corresponds to advanced disease and sensitivity to drugs targeting pro-survival signaling and DNA replication. Third, homozygous CALR mutations result in high ER stress, responding to ER stressors and UPR inhibition. Overall, our integrated analyses provide a molecularly-motivated roadmap for individualized MF patient treatment.

2023-10-12 | PXD036075 | Pride

Genetic alterations associated with multiple primary malignancies

Project description:Affymetrix OncoScan arrays were used to identify potential driver DNA copy number alterations and somatic mutations that promote the development of multiple primary malignancies in 26 breast cancer patients.

2021-07-14 | GSE165240 | GEO

RNA-seq of JAK2VF and DNMT3A mutant Myelofibrosis patients

Project description:Determination of differentially expressed genes from peripheral blood of Myelofibrosis patients with JAK2VF and JAK2VF and DNMT3A mutations

2018-12-01 | E-MTAB-7255 | biostudies-arrayexpress

Targeted DNA sequencing of uveal melanoma driver mutations

Project description:Targeted DNA sequencing of uveal melanoma driver mutations

| PRJNA1258314 | ENA